Purple biotech identifies potential new serum biomarker for its lead oncology therapeutic candidate cm24: associated with 79% reduction in risk of death

Patients with serum ceacam1 within a defined range prior to treatment demonstrated increased overall survival (os) and progression free survival (pfs) when treated with cm24

PPBT Ratings Summary

PPBT Quant Ranking